Appia Bio is an early-stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).

Biotechnology

Education

Appia Bio

JJ Kang

Sylvaine Cases

Monica Jenkins

Alex Babayan

V. Mitch Luna

Tessa Aglupos-McCann

Emily Lowe

David Moskowitz

David Morse

Beverley Moore

Jeff Wiezorek

Edmund Kim

Jason Damiano

The executive team at Appia Bio has a history in the biotechnology industry, with experience in cancer biology and biotherapeutics, antibody therapeutics, and in vivo pharmacology. The team also has a strong educational background, with degrees in cellular pharmacology/cancer biology and biology from the University of Arizona.

CEO and Executive Team

Leadership Team

Board of Directors

CEO and Executive Team

About

Team members

Other teams at Appia Bio

Leadership Team

Board of Directors